Jenks, Oklahoma – When Josh Austin received a stage 4 pancreatic cancer diagnosis in August 2024, the prognosis seemed bleak. After a Whipple surgery and a short course of traditional chemotherapy, his doctors warned him that his chances of surviving five years were only about 20 percent.
Rather than surrender to that outlook, Austin pursued a clinical trial at OU Health Stephenson Cancer Center in Oklahoma City. The trial tested daraxonrasib, an oral targeted therapy marketed as Rasonque, which attacks a specific KRAS protein pathway that fuels pancreatic tumors.
How the drug works
Dr. Susanna Ulahannan, a gastrointestinal oncologist and director of the Phase I Clinical Trials Program, explained that KRAS acts like an accelerator for cancer cells. “If you block that accelerator, the cancer stops,” she said. Austin’s tumor carried the KRAS mutation, making him eligible for the study. He began taking the pill in August 2025 and, more than a year later, reports that his disease has not spread.
“From what I’ve seen, it is amazing because it hasn’t, it hasn’t spread,” Austin said. While he stresses the drug is not a cure, it has given him a quality of life that chemotherapy could not.
Trial results show promise
The RASolute 302 trial enrolled roughly 500 patients with advanced pancreatic cancer. Participants receiving daraxonrasib experienced a median overall survival of 13.2 months, compared with 6.7 months for those on standard chemotherapy. Tumor response rates were about 30 percent versus 11 percent for chemotherapy.
Dr. Ulahannan noted the findings were especially meaningful because progress in pancreatic‑cancer treatment has been limited for decades. “When this data was presented in June 2026, there were standing ovations and tears,” she recalled. The drug received FDA approval in August 2026 for certain advanced‑stage patients.
Impact on Austin’s family life
Beyond the statistics, Austin emphasizes the personal benefits. He now works full‑time, has the energy to pursue hobbies after work, and has been able to attend his two children’s college graduations, travel to Alaska and Costa Rica, and enjoy family vacations.
“Sometimes there’s a little bit of pressure to enjoy every minute because you feel like you’ve been given this gift, right? Of getting to live, live longer,” he said.
Side effects and ongoing care
Targeted therapies are not without drawbacks. Austin reports skin irritation and acne‑like reactions that sometimes require medication. Dr. Ulahannan says clinicians monitor patients closely and can prescribe creams or preventive drugs to manage side effects.
Austin continues regular imaging every two months and monthly appointments. So far, scans show minimal remaining disease and no new spread.
What this means for other patients
Ulahannan believes the success of daraxonrasib could open doors for further research, including testing the drug in earlier disease stages or in combination with other treatments. She urges patients to discuss clinical‑trial options with their doctors, noting that trials rely on volunteers to advance medical knowledge.
For families like the Austins, the breakthrough offers not just extra months, but the chance to share meaningful moments together—a testament to the power of innovative medicine and the importance of community support.
Original reporting: KTUL 8 (Sinclair) – local — read the source article.